LAMCAK pilot study: urinary cathepsin K as a potential biomarker in lymphangioleiomyomatosis
<b>Pathophysiology of LAM could be partly explained by abnormal overexpression of proteases such as cathepsin K (CatK). In this pilot study, we found an increase in pro-CatK levels in LAM patients compared to healthy female volunteers.</b> https://bit.ly/46U3vAG.
Authors
- Thomas Flament (ORCID: https://orcid.org/0000-0003-0258-7856)
- Lise Vanderlynden
- S. Marchand‐Adam (ORCID: https://orcid.org/0000-0002-9522-3738)
- Marion Pronost
- Gilles Lalmanach (ORCID: https://orcid.org/0000-0001-8562-4821)
- Fabien Lecaille (ORCID: https://orcid.org/0000-0003-1060-4222)
Institutions
- Université de Tours (FR)
- Inserm (FR)
- Centre de recherche en Epidémiologie et Santé des Populations (FR)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1183/23120541.00279-2025
- Primary Topic
- Tuberous Sclerosis Complex Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00